Evidence map›Paper›PMID 34169675›Full record

ArticleThe world journal of men's health2022

Circ_0001686 Promotes Prostate Cancer Progression by Up-Regulating SMAD3/TGFBR2

Jiancheng Pan, Zihao Liu, Zhizhao Yang, Enli Liang, Cheng Fang, Dingrong Zhang, Xiaodong Zhou, Yuanjie Niu, Zhongcheng Xin, Yegang Chen and 1 more

Open access · diamondAbstract read
In one paragraph

Article in The world journal of men's health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. CircDUSP22 Attenuates the Ferroptosis of Prostate Cancer CellsCombinatorial chemistry & high throughput screening · 2025
    Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Jiancheng Pan *Department of Urology, the Second Hospital of Tianjin Medical University, Tianjin Institute of Urology, Tianjin, China.ORCID https://orcid.org/0000-0002-7703-7667
Zihao Liu *Department of Urology, the Second Hospital of Tianjin Medical University, Tianjin Institute of Urology, Tianjin, China.ORCID https://orcid.org/0000-0001-8820-729X
Zhizhao YangDepartment of Urology, the Second Hospital of Tianjin Medical University, Tianjin Institute of Urology, Tianjin, China.ORCID https://orcid.org/0000-0003-1734-0119
Enli LiangDepartment of Urology, the Second Hospital of Tianjin Medical University, Tianjin Institute of Urology, Tianjin, China.ORCID https://orcid.org/0000-0003-3079-3059
Cheng FangDepartment of Urology, the Second Hospital of Tianjin Medical University, Tianjin Institute of Urology, Tianjin, China.ORCID https://orcid.org/0000-0001-9083-5826
Dingrong ZhangDepartment of Urology, the Second Hospital of Tianjin Medical University, Tianjin Institute of Urology, Tianjin, China.ORCID https://orcid.org/0000-0001-6425-2969
Xiaodong ZhouDepartment of Urology, the Second Hospital of Tianjin Medical University, Tianjin Institute of Urology, Tianjin, China.ORCID https://orcid.org/0000-0003-1557-5053
Yuanjie NiuDepartment of Urology, the Second Hospital of Tianjin Medical University, Tianjin Institute of Urology, Tianjin, China.ORCID https://orcid.org/0000-0001-5514-8908
Zhongcheng XinDepartment of Urology, the Second Hospital of Tianjin Medical University, Tianjin Institute of Urology, Tianjin, China.ORCID https://orcid.org/0000-0002-0361-2737
Yegang ChenDepartment of Urology, the Second Hospital of Tianjin Medical University, Tianjin Institute of Urology, Tianjin, China. yegangchen@tmu.edu.cn.ORCID https://orcid.org/0000-0002-1984-3695
Qiliang Cai *Department of Urology, the Second Hospital of Tianjin Medical University, Tianjin Institute of Urology, Tianjin, China. caiqiliang@tmu.edu.cn.ORCID https://orcid.org/0000-0002-4273-0103
Second Hospital of Tianjin Medical University · CN

Funding

Tianjin Education Commission for Higher Education 2018KJ050
6 · The paper itself

Abstract

purposeAs the mechanism of interaction between circular RNAs (circRNAs) and microRNAs (miRNAs) in regulating the development of prostate cancer (PCa) is not clear, this study focuses on investigating these effects. MATERIALS AND

methodsSample tissues were collected from the PCa of patients, and microarray analysis of human circRNAs was conducted. The expression of circ_0001686, hsa_miR-411-5p (miR-411-5p) were also detected by qRT-PCR. Circ_0001686 and miR-411-5p mimics were transfected into the PCa cell lines (CWR22RV1and LNCaP) and MTT, colony formation, Transwell, and scratch wound assays were used to analyze the biological behaviors of PCa cells. Si-circ_0001686 and ASO-miR-411-5p were used as negative controls, and dual-luciferase reporter assays were performed to verify the interactions among circ_0001686, miR-411-5p, and SMAD3/TGFBR2. The levels of SMAD3 and TGFBR2 in different treated PCa cells were measured by western blot, and

resultsThe expression of circ_0001686 was up-regulated, while the expression of miR-411-5p was down-regulated in PCa cells. Moreover, circ_0001686 promoted cell proliferation, migration, and invasion. Molecular mechanism exploration revealed that circ_0001686 could reduce miR-411-5p, affecting the downstream target genes of SMAD3 and TGFBR2.

conclusionsCirc_0001686 can reduce miR-411-5p to increase the expression of SMAD3/TGFBR2, which consequently promotes the proliferation, invasion, and migration of PCa cells.

Indexed as

CircRNAmiRNAProstate cancer

Identifiers

PMID34169675
PMCPMC8761241
OpenAlexW3165175825

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.